< Back to latest news & events

Awards

IAM Strategy 300 2021

September 2021

IAM Strategy 300 Global Leaders guide has been published and HGF is delighted to have 4 Partners listed.

The guide draws from the worlds of private practice, consulting and other service providers, with specialists from the major IP markets in North America, Europe and Asia. Together they boast a wide range of expertise in IP-intensive sectors such as high-tech and life sciences.

HGF has 4 Partners listed in the guide in 2021:

Dr Andrew Wells

Hsu Min Chung

Douglas Drysdale

Dr Gary Wilson

Latest updates

Happy World IP Day!

This year’s theme is ‘IP and the SDGs: Building our common future with innovation and creativity’. At HGF we are committed to supporting our clients in sustainable technologies and routinely …

Read article

IP Ingredients, Part 12: Exploring colours in the food & drink sector – overcoming hurdles and leveraging colour trade marks

We will all recognise as consumers an instance of when we used the colour of a product or its packaging to identify a specific brand that we wanted to buy …

Read article

Medical 3D Technologies: From Scanning to Printing

When we think of 3D technologies, we often think of 3D printing, which, as discussed later, has seen rapid advances in recent years. However, a sometimes overlooked area of medical …

Read article

Opinion Piece: Unitary Patent and Unified Patent Court in Ireland

Intellectual Property (IP) is a core part of any business and particularly is a vital part of the strategic toolkit for any business that creates value through innovation and constant …

Read article

IP Ingredients Blog, Parts 11-20

Welcome to our blog series, IP Ingredients, created by our Food & Drink Team. This blog will explore the latest IP news, updates, and discussions in the food & drink …

Read article

EnteroBiotix Limited Secures £27m Financing Round to Advance Clinical Trials

We are pleased to congratulate EnteroBiotix, on their milestone in their journey towards revolutionising healthcare for patients battling gut-related ailments. The leading clinical-stage biotechnology company has successfully closed a £27 …

Read article